多发性骨髓瘤患者血浆suPAR水平的临床研究

为了探讨多发性骨髓瘤（MM）患者血浆尿激酶型纤溶酶原激活剂受体（suPAR）的变化,采用酶联免疫吸附测定方法（ELISA）检测26例多发性骨髓瘤患者的suPAR水平,并常规检查其他临床指标的变化。研究结果表明：MM患者血浆suPAR水平为4.31±1.67ng/ml,明显高于正常对照组（1.87±0.27ng/ml）（p〈0.01）。IgM型患者血浆suPAR水平最高（6.18±3.61ng/ml）,尔后依次为不分泌型、IgG型和IgA型（4.43±1.55ng/ml、4.00±0.95ng/ml、3.50±1.60ng/ml）。各亚型组均高于正常对照组,但各亚型组间无差异。患者suPAR水平与血沉、肌酐量、血红蛋白水平、浆细胞比值、M蛋白水平相关。结论：多发性骨髓瘤患者suPAR水平的变化有助于判断病情的发展和预后。

Plasma suPAR Level in Patients with Multiple Myeloma

To investigate the changes of plasma suPAR level in patients with multiple myeloma, ELISA was used to detect plasma suPAR level, and routine examination was performed for other clinical indexes in 26 multiple myeloma patients. The results showed that plasma suPAR level in patients was 4.31+/-1.67 ng/ml, which was obviously higher than that in control group (1.87+/-0.27 ng/ml) (p<0.01). Plasma suPAR level in IgM subtype patients was 6.18+/-3.61 ng/ml, which was highest among all the subtypes; the plasma suPAR levels in non-secretion subtype, IgG and IgA subtype were 4.43+/-1.55 ng/ml, 4.00+/-0.95 ng/ml and 3.50+/-1.60 ng/ml respectively. The plasma suPAR levels in all subtypes were higher than that in control group, but there was no differences between these subtypes. SuPAR level was correlated with the blood sedimentation rate, creatinine level and hemoglobin level, plasma cell ratio and M protein level. It is concluded that the change of plasma suPAR level in multiple myeloma contributes to predict the development and prognosis of the disease.